X4 Pharmaceuticals, Inc. (XFOR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

X4 Pharmaceuticals, Inc. (XFOR) closed at USD 2.45 on 2026-10-14, a change of -35.7 % over the past year, with a market capitalization of USD 261.75M.

X4 Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

X4 Pharmaceuticals, Inc. key figures

Previous close

USD 2.45 (2026-10-14)

1-year change

-35.7 %

Market cap

USD 261.75M

Enterprise value

USD 131M

P/E ratio (trailing)

132.00

P/E ratio (forward)

-3.44

EPS (trailing)

0.02

EPS (forward)

-0.77

PEG ratio

n/a

Price to book

1.63

Revenue growth

346.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.42

Employees

45

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for X4 Pharmaceuticals, Inc. and compare it with other stocks.